Jentsch Mike C, Van Buel Erin M, Bosker Fokko J, Gladkevich Anatoliy V, Klein Hans C, Oude Voshaar Richard C, Ruhé Eric G, Eisel Uli L M, Schoevers Robert A
University of Groningen, University Medical Centre of Groningen, University Centre of Psychiatry, Groningen, The Netherlands.
Biomark Med. 2015;9(3):277-97. doi: 10.2217/bmm.14.114.
Major depressive disorder is a heterogeneous disorder, mostly diagnosed on the basis of symptomatic criteria alone. It would be of great help when specific biomarkers for various subtypes and symptom clusters of depression become available to assist in diagnosis and subtyping of depression, and to enable monitoring and prognosis of treatment response. However, currently known biomarkers do not reach sufficient sensitivity and specificity, and often the relation to underlying pathophysiology is unclear. In this review, we evaluate various biomarker approaches in terms of scientific merit and clinical applicability. Finally, we discuss how combined biomarker approaches in both preclinical and clinical studies can help to make the connection between the clinical manifestations of depression and the underlying pathophysiology.
重度抑郁症是一种异质性疾病，主要仅根据症状标准进行诊断。当可获得针对抑郁症各种亚型和症状群的特定生物标志物，以协助抑郁症的诊断和亚型划分，并实现对治疗反应的监测和预后评估时，将大有帮助。然而，目前已知的生物标志物未达到足够的敏感性和特异性，而且其与潜在病理生理学的关系往往不明确。在本综述中，我们从科学价值和临床适用性方面评估了各种生物标志物方法。最后，我们讨论了临床前和临床研究中的联合生物标志物方法如何有助于建立抑郁症临床表现与潜在病理生理学之间的联系。
Zotero 插件